THE Generic Medicines Working Group (GMWG) has identified initial policy priorities and summarised them in their 09 Sep Communiqu.
The first of the four priorities was described as pricing policy, supply and viability following price disclosure changes and improving access for consumers.
Secondly, the Generic and Biosimilar Medicines Association (GBMA) highlighted the importance of supporting the uptake of generic medicines, and that it was important to minimise any move back to innovator brands.
Biosimilars were the next issue with plans to develop awareness and confidence in these products.
Finally the Health Department said it wants transparency around PBS processes for biosimilars to broaden understanding.
CLICK HERE for the Communiqu.
The above article was sent to subscribers in Pharmacy Daily's issue from 21 Sep 16
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 21 Sep 16